Cargando…

ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia

Heparin-induced thrombocytopenia (HIT) is an unpredictable, potentially catastrophic adverse effect resulting from an immune response to platelet factor 4 (PF4)/heparin complexes. We performed a genome-wide association study (GWAS) with positive functional assay as the outcome in a large discovery c...

Descripción completa

Detalles Bibliográficos
Autores principales: Karnes, Jason H., Rollin, Jerome, Giles, Jason B., Martinez, Kiana L., Steiner, Heidi E., Shaffer, Christian M., Momozawa, Yukihide, Inai, Chihiro, Bombin, Andrei, Shi, Mingjian, Mosley, Jonathan D., Stanaway, Ian, Selleng, Kathleen, Thiele, Thomas, Mushiroda, Taisei, Pouplard, Claire, Heddle, Nancy M., Kubo, Michiaki, Phillips, Elizabeth J., Warkentin, Theodore E., Gruel, Yves, Greinacher, Andreas, Roden, Dan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305089/
https://www.ncbi.nlm.nih.gov/pubmed/35377938
http://dx.doi.org/10.1182/blood.2021014240
_version_ 1784752239338848256
author Karnes, Jason H.
Rollin, Jerome
Giles, Jason B.
Martinez, Kiana L.
Steiner, Heidi E.
Shaffer, Christian M.
Momozawa, Yukihide
Inai, Chihiro
Bombin, Andrei
Shi, Mingjian
Mosley, Jonathan D.
Stanaway, Ian
Selleng, Kathleen
Thiele, Thomas
Mushiroda, Taisei
Pouplard, Claire
Heddle, Nancy M.
Kubo, Michiaki
Phillips, Elizabeth J.
Warkentin, Theodore E.
Gruel, Yves
Greinacher, Andreas
Roden, Dan M.
author_facet Karnes, Jason H.
Rollin, Jerome
Giles, Jason B.
Martinez, Kiana L.
Steiner, Heidi E.
Shaffer, Christian M.
Momozawa, Yukihide
Inai, Chihiro
Bombin, Andrei
Shi, Mingjian
Mosley, Jonathan D.
Stanaway, Ian
Selleng, Kathleen
Thiele, Thomas
Mushiroda, Taisei
Pouplard, Claire
Heddle, Nancy M.
Kubo, Michiaki
Phillips, Elizabeth J.
Warkentin, Theodore E.
Gruel, Yves
Greinacher, Andreas
Roden, Dan M.
author_sort Karnes, Jason H.
collection PubMed
description Heparin-induced thrombocytopenia (HIT) is an unpredictable, potentially catastrophic adverse effect resulting from an immune response to platelet factor 4 (PF4)/heparin complexes. We performed a genome-wide association study (GWAS) with positive functional assay as the outcome in a large discovery cohort of patients divided into 3 groups: (1) functional assay-positive cases (n = 1269), (2) antibody-positive (functional assay-negative) controls (n = 1131), and (3) antibody-negative controls (n = 1766). Significant associations (α = 5 × 10(−8)) were investigated in a replication cohort (α = 0.05) of functional assay-confirmed HIT cases (n = 177), antibody-positive (function assay-negative) controls (n = 258), and antibody-negative controls (n = 351). We observed a strong association for positive functional assay with increasing PF4/heparin immunoglobulin-G (IgG) level (odds ratio [OR], 16.53; 95% confidence interval [CI], 13.83-19.74; P = 1.51 × 10(−209)) and female sex (OR, 1.15; 95% CI, 1.01-1.32; P = .034). The rs8176719 C insertion variant in ABO was significantly associated with positive functional assay status in the discovery cohort (frequency = 0.41; OR, 0.751; 95% CI, 0.682-0.828; P = 7.80 × 10(−9)) and in the replication cohort (OR, 0.467; 95% CI, 0.228-0.954; P = .0367). The rs8176719 C insertion, which encodes all non-O blood group alleles, had a protective effect, indicating that the rs8176719 C deletion and the O blood group were risk factors for HIT (O blood group OR, 1.42; 95% CI, 1.26-1.61; P = 3.09 × 10(−8)). Meta-analyses indicated that the ABO association was independent of PF4/heparin IgG levels and was stronger when functional assay-positive cases were compared with antibody-positive (functional assay-negative) controls than with antibody-negative controls. Sequencing and fine-mapping of ABO demonstrated that rs8176719 was the causal single nucleotide polymorphism (SNP). Our results clarify the biology underlying HIT pathogenesis with ramifications for prediction and may have important implications for related conditions, such as vaccine-induced thrombotic thrombocytopenia.
format Online
Article
Text
id pubmed-9305089
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-93050892022-11-16 ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia Karnes, Jason H. Rollin, Jerome Giles, Jason B. Martinez, Kiana L. Steiner, Heidi E. Shaffer, Christian M. Momozawa, Yukihide Inai, Chihiro Bombin, Andrei Shi, Mingjian Mosley, Jonathan D. Stanaway, Ian Selleng, Kathleen Thiele, Thomas Mushiroda, Taisei Pouplard, Claire Heddle, Nancy M. Kubo, Michiaki Phillips, Elizabeth J. Warkentin, Theodore E. Gruel, Yves Greinacher, Andreas Roden, Dan M. Blood Thrombosis and Hemostasis Heparin-induced thrombocytopenia (HIT) is an unpredictable, potentially catastrophic adverse effect resulting from an immune response to platelet factor 4 (PF4)/heparin complexes. We performed a genome-wide association study (GWAS) with positive functional assay as the outcome in a large discovery cohort of patients divided into 3 groups: (1) functional assay-positive cases (n = 1269), (2) antibody-positive (functional assay-negative) controls (n = 1131), and (3) antibody-negative controls (n = 1766). Significant associations (α = 5 × 10(−8)) were investigated in a replication cohort (α = 0.05) of functional assay-confirmed HIT cases (n = 177), antibody-positive (function assay-negative) controls (n = 258), and antibody-negative controls (n = 351). We observed a strong association for positive functional assay with increasing PF4/heparin immunoglobulin-G (IgG) level (odds ratio [OR], 16.53; 95% confidence interval [CI], 13.83-19.74; P = 1.51 × 10(−209)) and female sex (OR, 1.15; 95% CI, 1.01-1.32; P = .034). The rs8176719 C insertion variant in ABO was significantly associated with positive functional assay status in the discovery cohort (frequency = 0.41; OR, 0.751; 95% CI, 0.682-0.828; P = 7.80 × 10(−9)) and in the replication cohort (OR, 0.467; 95% CI, 0.228-0.954; P = .0367). The rs8176719 C insertion, which encodes all non-O blood group alleles, had a protective effect, indicating that the rs8176719 C deletion and the O blood group were risk factors for HIT (O blood group OR, 1.42; 95% CI, 1.26-1.61; P = 3.09 × 10(−8)). Meta-analyses indicated that the ABO association was independent of PF4/heparin IgG levels and was stronger when functional assay-positive cases were compared with antibody-positive (functional assay-negative) controls than with antibody-negative controls. Sequencing and fine-mapping of ABO demonstrated that rs8176719 was the causal single nucleotide polymorphism (SNP). Our results clarify the biology underlying HIT pathogenesis with ramifications for prediction and may have important implications for related conditions, such as vaccine-induced thrombotic thrombocytopenia. American Society of Hematology 2022-07-21 /pmc/articles/PMC9305089/ /pubmed/35377938 http://dx.doi.org/10.1182/blood.2021014240 Text en © 2022 by The American Society of Hematology. https://creativecommons.org/licenses/by-nc-nd/4.0/Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
spellingShingle Thrombosis and Hemostasis
Karnes, Jason H.
Rollin, Jerome
Giles, Jason B.
Martinez, Kiana L.
Steiner, Heidi E.
Shaffer, Christian M.
Momozawa, Yukihide
Inai, Chihiro
Bombin, Andrei
Shi, Mingjian
Mosley, Jonathan D.
Stanaway, Ian
Selleng, Kathleen
Thiele, Thomas
Mushiroda, Taisei
Pouplard, Claire
Heddle, Nancy M.
Kubo, Michiaki
Phillips, Elizabeth J.
Warkentin, Theodore E.
Gruel, Yves
Greinacher, Andreas
Roden, Dan M.
ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
title ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
title_full ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
title_fullStr ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
title_full_unstemmed ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
title_short ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
title_sort abo o blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
topic Thrombosis and Hemostasis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305089/
https://www.ncbi.nlm.nih.gov/pubmed/35377938
http://dx.doi.org/10.1182/blood.2021014240
work_keys_str_mv AT karnesjasonh aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT rollinjerome aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT gilesjasonb aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT martinezkianal aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT steinerheidie aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT shafferchristianm aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT momozawayukihide aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT inaichihiro aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT bombinandrei aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT shimingjian aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT mosleyjonathand aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT stanawayian aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT sellengkathleen aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT thielethomas aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT mushirodataisei aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT pouplardclaire aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT heddlenancym aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT kubomichiaki aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT phillipselizabethj aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT warkentintheodoree aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT gruelyves aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT greinacherandreas aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia
AT rodendanm aboobloodgroupasariskfactorforplateletreactivityinheparininducedthrombocytopenia